SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following news of a multi-billion dollar AI cloud services contract with Microsoft, leading to significant price movement. The community is buzzing about the potential impact of this deal, particularly regarding IREN's position in the AI cloud infrastructure space. This news underscores the growing demand for AI infrastructure and IREN's role in meeting that demand.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its small float and potential for a significant breakout, with many traders eyeing a move past key resistance levels. The stock is gaining attention across social media platforms, fueling speculation of a potential short squeeze and parabolic run. Community members are closely monitoring volume and price action, anticipating a substantial upward move.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with community chatter focused on the company's potential for growth within the AI sector. Some are discussing the possibility of a stock split announcement, while others debate the stock's high valuation and potential for a post-earnings pullback, as well as a lawsuit against former employees that will likely be brought up during the earnings call.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies Inc. is trending as investors discuss its correlation with Ethereum's recent price volatility and potential impact on the company's Q4 ETH treasury performance. Community members are debating whether recent price action represents a buying opportunity or signals a deeper downturn, and are closely watching for updates from Tom Lee on the company's strategy and Ethereum price targets. Some traders express frustration and question the company's performance relative to direct ETH exposure.

Superfruits AI is redefining the Web3 landscape with an ecosystem of fruit-themed AI agents offering specialized insights and services, ranging from blockchain security to market sentiment analysis. Building on this vibrant foundation, we're introducing groundbreaking features like a proprietary Web3-trained AI model, an interactive Virtual Research Room, and the innovative concept of "Juices." These "Juices" empower high token holders to mix and match agents' capabilities, creating custom virtual rooms where agents collaborate on tailored analyses for portfolios or projects. By blending cutting-edge AI with gamified user experiences, Superfruits AI positions itself as a pioneer in Web3 analytics, offering unique tools that not only secure but also enrich the decentralized journey for every user.

SuperFruits AI

SuperFruits AI ($SUPAI) is trending as community members highlight its potential breakout, citing strong chart patterns and AI-driven innovation. There's a focus on the strength of its community and the belief that $SUPAI is on the verge of significant upward movement, while maintaining controlled and consistent chart behavior. The community emphasizes patience and strategic execution, suggesting confidence in the long-term vision.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss potential catalysts following IREN's AI cloud contract, with anticipation building for CIFR's upcoming earnings and potential deals in the AI infrastructure space. Community members are weighing the potential impact of earnings on the stock's price, with some expressing concerns about hype and potential pullbacks. Bullish sentiment remains, driven by the company's positioning in the AI sector and expectations for significant growth.

Chime Financial, Inc. engages in the design and development of a digital banking application. Its mobile app, Chime, provides online banking, fee-free overdraft, mobile banking, automatic savings, mobile payments, and security and control capabilities. The company was founded by Christopher R. Britt and Ryan King in 2012 and is headquartered in San Francisco, CA.

Chime Financial Inc - Ordinary Shares - Class A

Chime Financial, Inc.

Chime Financial ($CHYM) is trending due to discussions around its valuation after a recent price decline and ahead of upcoming earnings. The community is debating whether it's undervalued, drawing comparisons to competitors like SoFi, while also considering factors like revenue growth and stock-based compensation. Some analysts maintain a positive outlook, while others express concerns about profitability and competition.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending due to positive analyst ratings and a potential breakout driven by strong momentum and new tax credits, with community discussions focusing on its attractive valuation and long-term growth potential. Recent positive earnings reports and a raised sales outlook have further fueled optimism, despite industry risks and commentary around subsidies. Community members speculate on potential price targets and the impact of broader market trends.

Phoenix Education Partners, Inc. engages in the provision of access to higher education opportunities that help students develop knowledge and skills. It operates through its subsidiary, the University of Phoenix. The company was founded on January 9, 2014 and is headquartered in Phoenix, AZ.

Phoenix Education Partners Inc

Phoenix Education Partners, Inc.

Phoenix Education Partners ($PXED) is trending following its recent IPO, with the community actively discussing its valuation relative to peers and potential upside. Several analysts have initiated coverage with positive ratings, while investors are weighing the company's strong financials and growth prospects against risks such as reliance on Title IV funding and private equity ownership.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending amid community discussions about its potential and future developments. Some users are focused on price predictions, while others are anticipating exchange listings. The community remains engaged, with many expressing long-term commitment to the project.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Stock Index Futures Slip as Tariff-Driven Selloff Continues, U.S. Jobs Report and Powell Speech in Focus

June S&P 500 E-Mini futures (ESM25) are down -0.84%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.52% this morning, pointing to a continued selloff on Wall Street following U.S. President Donald Trump’s announcement of sweeping tariffs, while investors await the key U.S. payrolls report and remarks from Federal Reserve Chair Jerome Powell.

Shares of Eli Lilly &amp; Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by fears of a global economic fallout from President Donald Trump’s reciprocal tariff blitz.However, retail investors took heart in the fact that the pharmaceutical industry suffered a relatively lighter blow compared to sectors like technology and manufacturing, as it was largely spared from the government’s targeted tariff list.On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’<figure class="image"><img style="aspect-ratio:1314/320;" src="https://news.stocktwits-cdn.com/LLY_sentiment_and_message_volume_on_April_3_png_0331ef626f.webp" alt="LLY sentiment and message volume on April 3.png" width="1314" height="320"><figcaption>LLY sentiment and message volume on April 3. | source: Stocktwits</figcaption></figure>“LLY isn’t even affected. Loading up on calls at the open!” one user posted early Thursday when the stock was still in the green.<stembedurl>https://stocktwits.com/DayTrader6969/message/610222644</stembedurl>Another user pointed out that Trump had specifically highlighted Lilly as a company investing in U.S. infrastructure and job creation, suggesting it could ultimately benefit from the administration’s policies.<stembedurl>https://stocktwits.com/MrChoudhury/message/610228354</stembedurl>Back in February, when Trump threatened to impose tariffs on drug imports, Lilly unveiled a plan to invest $27 billion on new plants in the United States over the next five years.However, as drugmakers dig through the fine print of Trump's sweeping executive order — which imposes a 10% baseline duty on most imports — uncertainty remains over whether the pharmaceutical industry will be completely spared.Media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/pharma-stocks-up-on-us-tariff-exemptions-but-analyst-flags-a-46b-import-cost-risk-3964936">reports</a> suggest a U.S. official hinted that a separate round of tariffs targeting pharmaceuticals is still on the table.According to Bernstein analysts, if country-specific tariffs are applied, the pharmaceutical industry could face up to $46 billion in additional import costs.For now, investors seem to be taking a small win in stride.Retail traders on Thursday also zeroed in on Lilly’s newly inked licensing deal with Sangamo Therapeutics for its adeno-associated virus capsid,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgmo-stock-falls-after-q4-2024-earnings-miss/ch7KGZ9Rbca">STAC-BBB</a>, designed to improve the delivery of IV-administered genomic medicines for neurological diseases.The deal grants Lilly exclusive global rights to use STAC-BBB for one initial central nervous system target, with the option to expand to four more for additional fees.Lilly's stock has gained a little over 1% this year, while the Dow Jones U.S. Health Care Index is up over 2.5% and the S&amp;P 500 Health Care Index has risen over 4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption

On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 

Equity

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SGMO News

SGMOSangamo Therapeutics Inc